The biochemistry of activation-induced deaminase and its physiological functions

Seminars in Immunology

Volumn 24, Issue 4, 2012, Pages 255-263

  Larijani, Mani ^a   Martin, Alberto ^b  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Activation induced deaminase; Antibody; B cell; Somatic hypermutation, Class switch recombination, Gene conversion

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; DNA BINDING PROTEIN; IMMUNOGLOBULIN; SINGLE STRANDED DNA;

ADAPTIVE IMMUNITY; AMINO ACID SEQUENCE; ATOMIC FORCE MICROSCOPY; B LYMPHOCYTE; BIOCHEMISTRY; CANCER CELL CULTURE; CATALYSIS; DEAMINATION; DNA REPLICATION; DNA STRAND BREAKAGE; ENZYME ACTIVITY; ENZYME STRUCTURE; GENE DUPLICATION; GENE LOCUS; GENE REARRANGEMENT; GENOME; HUMAN; IMMUNE RESPONSE; IMMUNOPRECIPITATION; IN VITRO STUDY; MUTAGENESIS; MUTATION RATE; NONHUMAN; NUCLEAR EXPORT SIGNAL; PHYSIOLOGY; PROTEIN DNA INTERACTION; PROTEIN QUATERNARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; REVIEW; SOMATIC HYPERMUTATION;

ADAPTIVE IMMUNITY; ANIMALS; BIOCATALYSIS; CYTIDINE DEAMINASE; ENZYME ACTIVATION; HUMANS; SUBSTRATE SPECIFICITY;

EID: 84865177920     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2012.05.003     Document Type: Review

References (149)

1. Rajewsky K. Clonal selection and learning in the antibody system. Nature 1996, 381:751-758.
2. Martin A., Scharff M.D. AID and mismatch repair in antibody diversification. Nature Reviews Immunology 2002, 2:605-614.
3. Chaudhuri J., Basu U., Zarrin A., Yan C., Franco S., Perlot T., et al. Evolution of the immunoglobulin heavy chain class switch recombination mechanism. Advances in Immunology 2007, 94:157-214.
4. Muramatsu M., Kinoshita K., Fagarasan S., Yamada S., Shinkai Y., Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000, 102:553-563.
5. Muramatsu M., Sankaranand V.S., Anant S., Sugai M., Kinoshita K., Davidson N.O., et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. The Journal of Biological Chemistry 1999, 274:18470-18476.
6. Revy P., Muto T., Levy Y., Geissmann F., Plebani A., Sanal O., et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell 2000, 102:565-575.
7. Durandy A., Revy P., Fischer A. Hyper-immunoglobulin-M syndromes caused by an intrinsic B cell defect. Current Opinion in Allergy and Clinical Immunology 2003, 3:421-425.
8. Meyers G., Ng Y.S., Bannock J.M., Lavoie A., Walter J.E., Notarangelo L.D., et al. Activation-induced cytidine deaminase (AID) is required for B-cell tolerance in humans. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:11554-11559.
9. Kuraoka M., Holl T.M., Liao D., Womble M., Cain D.W., Reynolds A.E., et al. Activation-induced cytidine deaminase mediates central tolerance in B cells. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:11560-11565.
10. Jiang C., Foley J., Clayton N., Kissling G., Jokinen M., Herbert R., et al. Abrogation of lupus nephritis in activation-induced deaminase-deficient MRL/lpr mice. Journal of Immunology 2007, 178:7422-7431.
11. Zaheen A., Martin A. Activation-induced cytidine deaminase and aberrant germinal center selection in the development of humoral autoimmunities. The American Journal of Pathology 2011, 178:462-471.
12. Ramiro A.R., Jankovic M., Eisenreich T., Difilippantonio S., Chen-Kiang S., Muramatsu M., et al. AID is required for c-myc/IgH chromosome translocations in vivo. Cell 2004, 118:431-438.
13. Robbiani D.F., Bothmer A., Callen E., Reina-San-Martin B., Dorsett Y., Difilippantonio S., et al. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell 2008, 135:1028-1038.
14. Pasqualucci L., Bhagat G., Jankovic M., Compagno M., Smith P., Muramatsu M., et al. AID is required for germinal center-derived lymphomagenesis. Nature Genetics 2008, 40:108-112.
15. Klemm L., Duy C., Iacobucci I., Kuchen S., von Levetzow G., Feldhahn N., et al. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell 2009, 16:232-245.
16. Martin A., Bardwell P.D., Woo C.J., Fan M., Shulman M.J., Scharff M.D. Activation-induced cytidine deaminase turns on somatic hypermutation in hybridomas. Nature 2002, 415:802-806.
17. Yoshikawa K., Okazaki I.M., Eto T., Kinoshita K., Muramatsu M., Nagaoka H., et al. AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts. Science 2002, 296:2033-2036.
18. Petersen-Mahrt S.K., Harris R.S., Neuberger M.S. AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature 2002, 418:99-104.
19. Nowak U., Matthews A.J., Zheng S., Chaudhuri J. The splicing regulator PTBP2 interacts with the cytidine deaminase. Nature Immunology 2011, 12:160-166.
20. Ranjit S., Khair L., Linehan E.K., Ucher A.J., Chakrabarti M., Schrader C.E., et al. AID binds cooperatively with UNG and Msh2-Msh6 to Ig switch regions dependent upon the AID C terminus. Journal of Immunology 2011, 187:2464-2475.
21. Bransteitter R., Pham P., Scharff M.D., Goodman M.F. Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:4102-4107.
22. Dickerson S.K., Market E., Besmer E., Papavasiliou F.N. AID mediates hypermutation by deaminating single stranded DNA. The Journal of Experimental Medicine 2003, 197:1291-1296.
23. Larijani M., Martin A. Single-stranded DNA structure and positional context of the target cytidine determine the enzymatic efficiency of AID. Molecular and Cellular Biology 2007, 27:8038-8048.
24. Pham P., Bransteitter R., Petruska J., Goodman M.F. Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation. Nature 2003, 424:103-107.
25. Di Noia J., Neuberger M.S. Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase. Nature 2002, 419:43-48.
26. Rada C., Di Noia J.M., Neuberger M.S. Mismatch recognition and uracil excision provide complementary paths to both Ig switching and the A/T-focused phase of somatic mutation. Molecular Cell 2004, 16:163-171.
27. Larijani M., Frieder D., Basit W., Martin A. The mutation spectrum of purified AID is similar to the mutability index in Ramos cells and in ung(-/-)msh2(-/-) mice. Immunogenetics 2005, 56:840-845.
28. - mice. The Journal of Experimental Medicine 2006, 203:2085-2094.
29. Sohail A., Klapacz J., Samaranayake M., Ullah A., Bhagwat A.S. Human activation-induced cytidine deaminase causes transcription-dependent, strand-biased C to U deaminations. Nucleic Acids Research 2003, 31:2990-2994.
30. Yu K., Huang F.T., Lieber M.R. DNA substrate length and surrounding sequence affect the activation-induced deaminase activity at cytidine. The Journal of Biological Chemistry 2004, 279:6496-6500.
31. Conticello S.G., Langlois M.A., Yang Z., Neuberger M.S. DNA deamination in immunity: AID in the context of its APOBEC relatives. Advances in Immunology 2007, 94:37-73.
32. Chiu Y.L., Greene W.C. APOBEC3 cytidine deaminases: distinct antiviral actions along the retroviral life cycle. The Journal of Biological Chemistry 2006, 281:8309-8312.
33. Conticello S.G. The AID/APOBEC family of nucleic acid mutators. Genome Biology 2008, 9:229.
34. Conticello S.G., Thomas C.J., Petersen-Mahrt S.K., Neuberger M.S. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Molecular Biology and Evolution 2005, 22:367-377.
35. Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J., et al. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 2002, 79:285-296.
36. Chiu Y.L., Greene W.C. APOBEC3G: an intracellular centurion. Philosophical Transactions of the Royal Society of London: Series B, Biological Sciences 2009, 364:689-703.
37. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., et al. DNA deamination mediates innate immunity to retroviral infection. Cell 2003, 113:803-809.
38. Yu Q., Konig R., Pillai S., Chiles K., Kearney M., Palmer S., et al. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nature Structural & Molecular Biology 2004, 11:435-442.
39. Albin J.S., Harris R.S. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Reviews in Molecular Medicine 2010, 12:e4.
40. Barreto V.M., Magor B.G. Activation-induced cytidine deaminase structure and functions: a species comparative view. Developmental and Compartive Immunology 2011, 35:991-1007.
41. Pancer Z., Cooper M.D. The evolution of adaptive immunity. Annual Review of Immunology 2006, 24:497-518.
42. Flajnik M.F., Kasahara M. Origin and evolution of the adaptive immune system: genetic events and selective pressures. Nature Reviews: Genetics 2010, 11:47-59.
43. Tasumi S., Velikovsky C.A., Xu G., Gai S.A., Wittrup K.D., Flajnik M.F., et al. High-affinity lamprey VLRA and VLRB monoclonal antibodies. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:12891-12896.
44. Deng L., Velikovsky C.A., Xu G., Iyer L.M., Tasumi S., Kerzic M.C., et al. A structural basis for antigen recognition by the T cell-like lymphocytes of sea lamprey. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:13408-13413.
45. Rogozin I.B., Iyer L.M., Liang L., Glazko G.V., Liston V.G., Pavlov Y.I., et al. Evolution and diversification of lamprey antigen receptors: evidence for involvement of an AID-APOBEC family cytosine deaminase. Nature Immunology 2007, 8:647-656.
46. Ko T.P., Lin J.J., Hu C.Y., Hsu Y.H., Wang A.H., Liaw S.H. Crystal structure of yeast cytosine deaminase. Insights into enzyme mechanism and evolution. The Journal of Biological Chemistry 2003, 278:19111-19117.
47. Losey H.C., Ruthenburg A.J., Verdine G.L. Crystal structure of Staphylococcus aureus tRNA adenosine deaminase TadA in complex with RNA. Nature Structural & Molecular Biology 2006, 13:153-159.
48. Prochnow C., Bransteitter R., Klein M.G., Goodman M.F., Chen X.S. The APOBEC-2 crystal structure and functional implications for the deaminase AID. Nature 2007, 445:447-451.
49. Chen K.M., Harjes E., Gross P.J., Fahmy A., Lu Y., Shindo K., et al. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 2008, 452:116-119.
50. Holden L.G., Prochnow C., Chang Y.P., Bransteitter R., Chelico L., Sen U., et al. Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 2008, 456:121-124.
51. Xiang S., Short S.A., Wolfenden R., Carter C.W. The structure of the cytidine deaminase-product complex provides evidence for efficient proton transfer and ground-state destabilization. Biochemistry 1997, 36:4768-4774.
52. Durandy A., Peron S., Taubenheim N., Fischer A. Activation-induced cytidine deaminase: structure-function relationship as based on the study of mutants. Human Mutation 2006, 27:1185-1191.
53. Brar S.S., Watson M., Diaz M. Activation-induced cytosine deaminase (AID) is actively exported out of the nucleus but retained by the induction of DNA breaks. The Journal of Biological Chemistry 2004, 279:26395-26401.
54. McBride K.M., Barreto V., Ramiro A.R., Stavropoulos P., Nussenzweig M.C. Somatic hypermutation is limited by CRM1-dependent nuclear export of activation-induced deaminase. The Journal of Experimental Medicine 2004, 199:1235-1244.
55. Patenaude A.M., Orthwein A., Hu Y., Campo V.A., Kavli B., Buschiazzo A., et al. Active nuclear import and cytoplasmic retention of activation-induced deaminase. Nature Structural & Molecular Biology 2009, 16:517-527.
56. Ireton G.C., Black M.E., Stoddard B.L. The 1.14Å crystal structure of yeast cytosine deaminase: evolution of nucleotide salvage enzymes and implications for genetic chemotherapy. Structure 2003, 11:961-972.
57. Carter C.W. The nucleoside deaminases for cytidine and adenosine: structure, transition state stabilization, mechanism, and evolution. Biochimie 1995, 77:92-98.
58. Larijani M., Petrov A.P., Kolenchenko O., Berru M., Krylov S.N., Martin A. AID associates with single-stranded DNA with high affinity and a long complex half-life in a sequence-independent manner. Molecular and Cellular Biology 2007, 27:20-30.
59. Wang M., Yang Z., Rada C., Neuberger M.S. AID upmutants isolated using a high-throughput screen highlight the immunity/cancer balance limiting DNA deaminase activity. Nature Structural & Molecular Biology 2009, 16:769-776.
60. Ta V.T., Nagaoka H., Catalan N., Durandy A., Fischer A., Imai K., et al. AID mutant analyses indicate requirement for class-switch-specific cofactors. Nature Immunology 2003, 4:843-848.
61. Brar S.S., Sacho E.J., Tessmer I., Croteau D.L., Erie D.A., Diaz M. Activation-induced deaminase, AID, is catalytically active as a monomer on single-stranded DNA. DNA Repair (Amsterdam) 2008, 7:77-87.
62. Stephens O.M., Yi-Brunozzi H.Y., Beal P.A. Analysis of the RNA-editing reaction of ADAR2 with structural and fluorescent analogues of the GluR-B R/G editing site. Biochemistry 2000, 39:12243-12251.
63. Holz B., Klimasauskas S., Serva S., Weinhold E. 2-Aminopurine as a fluorescent probe for DNA base flipping by methyltransferases. Nucleic Acids Research 1998, 26:1076-1083.
64. Slupphaug G., Mol C.D., Kavli B., Arvai A.S., Krokan H.E., Tainer J.A. A nucleotide-flipping mechanism from the structure of human uracil-DNA glycosylase bound to DNA. Nature 1996, 384:87-92.
65. Jiang Y.L., Stivers J.T., Song F. Base-flipping mutations of uracil DNA glycosylase: substrate rescue using a pyrene nucleotide wedge. Biochemistry 2002, 41:11248-11254.
66. Jiang Y.L., Kwon K., Stivers J.T. Turning on uracil-DNA glycosylase using a pyrene nucleotide switch. The Journal of Biological Chemistry 2001, 276:42347-42354.
67. Rogozin I.B., Kolchanov N.A. Somatic hypermutagenesis in immunoglobulin genes. II. Influence of neighbouring base sequences on mutagenesis. Biochimica et Biophysica Acta 1992, 1171:11-18.
68. Beale R.C., Petersen-Mahrt S.K., Watt I.N., Harris R.S., Rada C., Neuberger M.S. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. Journal of Molecular Biology 2004, 337:585-596.
69. Larijani M., Frieder D., Sonbuchner T.M., Bransteitter R., Goodman M.F., Bouhassira E.E., et al. Methylation protects cytidines from AID-mediated deamination. Molecular Immunology 2005, 42:599-604.
70. Morgan H.D., Dean W., Coker H.A., Reik W., Petersen-Mahrt S.K. Activation-induced cytidine deaminase deaminates 5-methylcytosine in DNA and is expressed in pluripotent tissues: implications for epigenetic reprogramming. The Journal of Biological Chemistry 2004, 279:52353-52360.
71. Rai K., Huggins I.J., James S.R., Karpf A.R., Jones D.A., Cairns B.R. DNA demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, and gadd45. Cell 2008, 135:1201-1212.
72. Bhutani N., Brady J.J., Damian M., Sacco A., Corbel S.Y., Blau H.M. Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature 2010, 463:1042-1047.
73. Kohli R.M., Abrams S.R., Gajula K.S., Maul R.W., Gearhart P.J., Stivers J.T. A portable hot spot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase. The Journal of Biological Chemistry 2009, 284:22898-22904.
74. Carpenter M.A., Rajagurubandara E., Wijesinghe P., Bhagwat A.S. Determinants of sequence-specificity within human AID and APOBEC3G. DNA Repair (Amsterdam) 2010, 9:579-587.
75. Wang M., Rada C., Neuberger M.S. Altering the spectrum of immunoglobulin V gene somatic hypermutation by modifying the active site of AID. The Journal of Experimental Medicine 2010, 207:141-153.
76. Yi-Brunozzi H.Y., Stephens O.M., Beal P.A. Conformational changes that occur during an RNA-editing adenosine deamination reaction. The Journal of Biological Chemistry 2001, 276:37827-37833.
77. Coker H.A., Morgan H.D., Petersen-Mahrt S.K. Genetic and in vitro assays of DNA deamination. Methods in Enzymology 2006, 408:156-170.
78. Pham P., Calabrese P., Park S.J., Goodman M.F. Analysis of a single-stranded DNA-scanning process in which activation-induced deoxycytidine deaminase (AID) deaminates C to U haphazardly and inefficiently to ensure mutational diversity. The Journal of Biological Chemistry 2011, 286:24931-24942.
79. Coker H.A., Petersen-Mahrt S.K. The nuclear DNA deaminase AID functions distributively whereas cytoplasmic APOBEC3G has a processive mode of action. DNA Repair (Amsterdam) 2007, 6:235-243.
80. Martin A., Li Z., Lin D.P., Bardwell P.D., Iglesias-Ussel M.D., Edelmann W., et al. Msh2 ATPase activity is essential for somatic hypermutation at A-T basepairs and for efficient class switch recombination. The Journal of Experimental Medicine 2003, 198:1171-1178.
81. Vallur A.C., Yabuki M., Larson E.D., Maizels N. AID in antibody perfection. Cellular and Molecular Life Sciences 2007, 64:555-565.
82. Dancyger A.M., King J.J., Quinlan M.J., Fifield H., Tucker S., Saunders H.L., et al. Differences in the enzymatic efficiency of human and bony fish AID are mediated by a single residue in the C terminus modulating single-stranded DNA binding. The FASEB Journal 2012, 26:1517-1525.
83. Di Noia J.M., Neuberger M.S. Immunoglobulin gene conversion in chicken DT40 cells largely proceeds through an abasic site intermediate generated by excision of the uracil produced by AID-mediated deoxycytidine deamination. European Journal of Immunology 2004, 34:504-508.
84. Imai K., Slupphaug G., Lee W.I., Revy P., Nonoyama S., Catalan N., et al. Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nature Immunology 2003, 4:1023-1028.
85. Saribasak H., Saribasak N.N., Ipek F.M., Ellwart J.W., Arakawa H., Buerstedde J.M. Uracil DNA glycosylase disruption blocks Ig gene conversion and induces transition mutations. Journal of Immunology 2006, 176:365-371.
86. Wiesendanger M., Kneitz B., Edelmann W., Scharff M.D. Somatic hypermutation in MutS homologue (MSH)3-, MSH6-, and MSH3/MSH6-deficient mice reveals a role for the MSH2-MSH6 heterodimer in modulating the base substitution pattern. The Journal of Experimental Medicine 2000, 191:579-584.
87. Rada C., Ehrenstein M.R., Neuberger M.S., Milstein C. Hot spot focusing of somatic hypermutation in MSH2-deficient mice suggests two stages of mutational targeting. Immunity 1998, 9:135-141.
88. Cascalho M., Wong J., Steinberg C., Wabl M. Mismatch repair co-opted by hypermutation. Science 1998, 279:1207-1210.
89. Phung Q.H., Winter D.B., Cranston A., Tarone R.E., Bohr V.A., Fishel R., et al. Increased hypermutation at G and C nucleotides in immunoglobulin variable genes from mice deficient in the MSH2 mismatch repair protein. The Journal of Experimental Medicine 1998, 187:1745-1751.
90. Kim N., Bozek G., Lo J.C., Storb U. Different mismatch repair deficiencies all have the same effects on somatic hypermutation: intact primary mechanism accompanied by secondary modifications. The Journal of Experimental Medicine 1999, 190:21-30.
91. Rada C., Williams G.T., Nilsen H., Barnes D.E., Lindahl T., Neuberger M.S. Immunoglobulin isotype switching is inhibited and somatic hypermutation perturbed in UNG-deficient mice. Current Biology 2002, 12:1748-1755.
92. Green B., Belcheva A., Nepal R.M., Boulianne B., Martin A. The mismatch repair pathway functions normally at a non-AID target in germinal center B cells. Blood 2011, 118:3013-3018.
93. Poltoratsky V., Woo C.J., Tippin B., Martin A., Goodman M.F., Scharff M.D. Expression of error-prone polymerases in BL2 cells activated for Ig somatic hypermutation. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:7976-7981.
94. Zeng X., Winter D.B., Kasmer C., Kraemer K.H., Lehmann A.R., Gearhart P.J. DNA polymerase eta is an A-T mutator in somatic hypermutation of immunoglobulin variable genes. Nature Immunology 2001, 2:537-541.
95. Zeng X., Negrete G.A., Kasmer C., Yang W.W., Gearhart P.J. Absence of DNA polymerase eta reveals targeting of C mutations on the nontranscribed strand in immunoglobulin switch regions. The Journal of Experimental Medicine 2004, 199:917-924.
96. Zan H., Komori A., Li Z., Cerutti A., Schaffer A., Flajnik M.F., et al. The translesion DNA polymerase zeta plays a major role in Ig and bcl-6 somatic hypermutation. Immunity 2001, 14:643-653.
97. Zan H., Shima N., Xu Z., Al-Qahtani A., Evinger Iii A.J., Zhong Y., et al. The translesion DNA polymerase theta plays a dominant role in immunoglobulin gene somatic hypermutation. The EMBO Journal 2005, 24:3757-3769.
98. Faili A., Aoufouchi S., Weller S., Vuillier F., Stary A., Sarasin A., et al. DNA polymerase eta is involved in hypermutation occurring during immunoglobulin class switch recombination. The Journal of Experimental Medicine 2004, 199:265-270.
99. Masuda K., Ouchida R., Hikida M., Kurosaki T., Yokoi M., Masutani C., et al. DNA polymerases eta and theta function in the same genetic pathway to generate mutations at A/T during somatic hypermutation of Ig genes. The Journal of Biological Chemistry 2007, 282:17387-17394.
100. Frieder D., Larijani M., Collins C., Shulman M., Martin A. The concerted action of Msh2 and UNG stimulates somatic hypermutation at A·T base pairs. Molecular and Cellular Biology 2009, 29:5148-5157.
101. Krijger P.H., Langerak P., van den Berk P.C., Jacobs H. Dependence of nucleotide substitutions on Ung2, Msh2, and PCNA-Ub during somatic hypermutation. The Journal of Experimental Medicine 2009, 206:2603-2611.
102. Martin A., Scharff M.D. Somatic hypermutation of the AID transgene in B and non-B cells. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:12304-12308.
103. Parsa J.Y., Basit W., Wang C.L., Gommerman J.L., Carlyle J.R., Martin A. AID mutates a non-immunoglobulin transgene independent of chromosomal position. Molecular Immunology 2007, 44:567-575.
104. Wang C.L., Harper R.A., Wabl M. Genome-wide somatic hypermutation. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:7352-7356.
105. Liu M., Duke J.L., Richter D.J., Vinuesa C.G., Goodnow C.C., Kleinstein S.H., et al. Two levels of protection for the B cell genome during somatic hypermutation. Nature 2008, 451:841-845.
106. Yamane A., Resch W., Kuo N., Kuchen S., Li Z., Sun H.W., et al. Deep-sequencing identification of the genomic targets of the cytidine deaminase AID and its cofactor RPA in B lymphocytes. Nature Immunology 2010, 12:62-69.
107. Upton D.C., Gregory B.L., Arya R., Unniraman S. AID: a riddle wrapped in a mystery inside an enigma. Immunologic Research 2011, 49:14-24.
108. Delker R.K., Fugmann S.D., Papavasiliou F.N. A coming-of-age story: activation-induced cytidine deaminase turns 10. Nature Immunology 2009, 10:1147-1153.
109. Orthwein A., Zahn A., Methot S.P., Godin D., Conticello S.G., Terada K., et al. Optimal functional levels of activation-induced deaminase specifically require the Hsp40 DnaJa1. The EMBO Journal 2011, 31:679-691.
110. Conticello S.G., Orthwein A., Patenaude A.M., Affar el B., Lamarre A., Young J.C., et al. Regulation of activation-induced deaminase stability and antibody gene diversification by Hsp90. The Journal of Experimental Medicine 2010, 207:2751-2765.
111. Han L., Masani S., Yu K. CTNNBL1 is dispensable for Ig class switch recombination. Journal of Immunology 2010, 185:1379-1381.
112. Conticello S.G., Ganesh K., Xue K., Lu M., Rada C., Neuberger M.S. Interaction between antibody-diversification enzyme AID and spliceosome-associated factor CTNNBL1. Molecular Cell 2008, 31:474-484.
113. Uchimura Y., Barton L.F., Rada C., Neuberger M.S. REG-gamma associates with and modulates the abundance of nuclear activation-induced deaminase. The Journal of Experimental Medicine 2011, 208:2385-2391.
114. Hasler J., Rada C., Neuberger M.S. Cytoplasmic activation-induced cytidine deaminase (AID) exists in stoichiometric complex with translation elongation factor 1alpha (eEF1A). Proceedings of the National Academy of Sciences of the United States of America 2011, 108:18366-18371.
115. Pavri R., Gazumyan A., Jankovic M., Di Virgilio M., Klein I., Ansarah-Sobrinho C., et al. Activation-induced cytidine deaminase targets DNA at sites of RNA polymerase II stalling by interaction with Spt5. Cell 2010, 143:122-133.
116. Basu U., Meng F.L., Keim C., Grinstein V., Pefanis E., Eccleston J., et al. The RNA exosome targets the AID cytidine deaminase to both strands of transcribed duplex DNA substrates. Cell 2011, 144:353-363.
117. Chaudhuri J., Khuong C., Alt F.W. Replication protein A interacts with AID to promote deamination of somatic hypermutation targets. Nature 2004, 430:992-998. 10.1038/nature02821.
118. Jeevan-Raj B.P., Robert I., Heyer V., Page A., Wang J.H., Cammas F., et al. Epigenetic tethering of AID to the donor switch region during immunoglobulin class switch recombination. The Journal of Experimental Medicine 2011, 208:1649-1660.
119. Okazaki I.M., Okawa K., Kobayashi M., Yoshikawa K., Kawamoto S., Nagaoka H., et al. Histone chaperone Spt6 is required for class switch recombination but not somatic hypermutation. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:7920-7925.
120. Basu U., Chaudhuri J., Alpert C., Dutt S., Ranganath S., Li G., et al. The AID antibody diversification enzyme is regulated by protein kinase A phosphorylation. Nature 2005, 438:508-511.
121. Pasqualucci L., Kitaura Y., Gu H., Dalla-Favera R. PKA-mediated phosphorylation regulates the function of activation-induced deaminase (AID) in B cells. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:395-400.
122. Demorest Z.L., MacDuff D.A., Brown W.L., Morham S.G., Parise L.V., Harris R.S. The interaction between AID and CIB1 is nonessential for antibody gene diversification by gene conversion or class switch recombination. PLoS One 2010, 5(7):e11660.
123. MacDuff D.A., Neuberger M.S., Harris R.S. MDM2 can interact with the C-terminus of AID but it is inessential for antibody diversification in DT40 B cells. Molecular Immunology 2006, 43:1099-1108.
124. Peters A., Storb U. Somatic hypermutation of immunoglobulin genes is linked to transcription initiation. Immunity 1996, 4:57-65.
125. Storb U., Peters A., Klotz E., Kim N., Shen H.M., Kage K., et al. Somatic hypermutation of immunoglobulin genes is linked to transcription. Current Topics in Microbiology and Immunology 1998, 229:11-19.
126. Fukita Y., Jacobs H., Rajewsky K. Somatic hypermutation in the heavy chain locus correlates with transcription. Immunity 1998, 9:105-114.
127. Lebecque S.G., Gearhart P.J. Boundaries of somatic mutation in rearranged immunoglobulin genes: 5' boundary is near the promoter, and 3' boundary is approximately 1kb from V(D)J gene. Journal of Experimental Medicine 1990, 172:1717-1727.
128. Rada C., Milstein C. The intrinsic hypermutability of antibody heavy and light chain genes decays exponentially. The EMBO Journal 2001, 20:4570-4576.
129. Rada C., Yelamos J., Dean W., Milstein C. The 5' hypermutation boundary of kappa chains is independent of local and neighbouring sequences and related to the distance from the initiation of transcription. European Journal of Immunology 1997, 27:3115-3120.
130. Bachl J., Carlson C., Gray-Schopfer V., Dessing M., Olsson C. Increased transcription levels induce higher mutation rates in a hypermutating cell line. Journal of Immunology 2001, 166:5051-5057.
131. Yang S.Y., Fugmann S.D., Schatz D.G. Control of gene conversion and somatic hypermutation by immunoglobulin promoter and enhancer sequences. The Journal of Experimental Medicine 2006, 203:2919-2928.
132. Dunnick W.A., Collins J.T., Shi J., Westfield G., Fontaine C., Hakimpour P., et al. Switch recombination and somatic hypermutation are controlled by the heavy chain 3' enhancer region. The Journal of Experimental Medicine 2009, 206:2613-2623.
133. Lin M.M., Green N.S., Zhang W., Scharff M.D. The effects of E mu, 3'alpha (hs 1,2) and 3'kappa enhancers on mutation of an Ig-VDJ-Cgamma2a Ig heavy gene in cultured B cells. International Immunology 1998, 10:1121-1129.
134. Michael N., Shen H.M., Longerich S., Kim N., Longacre A., The Storb U. E Box motif CAGGTG enhances somatic hypermutation without enhancing transcription. Immunity 2003, 19:235-242.
135. Bachl J., Olsson C., Chitkara N., Wabl M. The Ig mutator is dependent on the presence, position, and orientation of the large intron enhancer. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:2396-2399.
136. Klix N., Jolly C.J., Davies S.L., Bruggemann M., Williams G.T., Neuberger M.S. Multiple sequences from downstream of the J kappa cluster can combine to recruit somatic hypermutation to a heterologous, upstream mutation domain. European Journal of Immunology 1998, 28:317-326.
137. Blagodatski A., Batrak V., Schmidl S., Schoetz U., Caldwell R.B., Arakawa H., et al. A cis-acting diversification activator both necessary and sufficient for AID-mediated hypermutation. PLoS Genetics 2009, 5:e1000332.
138. Vincent-Fabert C., Fiancette R., Pinaud E., Truffinet V., Cogne N., Cogne M., et al. Genomic deletion of the whole IgH 3' regulatory region (hs3a, hs1,2, hs3b, and hs4) dramatically affects class switch recombination and Ig secretion to all isotypes. Blood 2010, 116:1895-1898.
139. Duquette M.L., Pham P., Goodman M.F., Maizels N. AID binds to transcription-induced structures in c-MYC that map to regions associated with translocation and hypermutation. Oncogene 2005, 24(38):5791-5798.
140. Besmer E., Market E., Papavasiliou F.N. The transcription elongation complex directs activation-induced cytidine deaminase-mediated DNA deamination. Molecular and Cellular Biology 2006, 26:4378-4385.
141. Shen H.M., Poirier M.G., Allen M.J., North J., Lal R., Widom J., et al. The activation-induced cytidine deaminase (AID) efficiently targets DNA in nucleosomes but only during transcription. The Journal of Experimental Medicine 2009, 206:1057-1071.
142. Shen H.M., Storb U. Activation-induced cytidine deaminase (AID) can target both DNA strands when the DNA is supercoiled. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:12997-13002.
143. Dayn A., Malkhosyan S., Mirkin S.M. Transcriptionally driven cruciform formation in vivo. Nucleic Acids Research 1992, 20:5991-5997.
144. Yu K., Chedin F., Hsieh C.L., Wilson T.E., Lieber M.R. R-loops at immunoglobulin class switch regions in the chromosomes of stimulated B cells. Nature Immunology 2003, 4:442-451.
145. Huang F.T., Yu K., Balter B.B., Selsing E., Oruc Z., Khamlichi A.A., et al. Sequence dependence of chromosomal R-loops at the immunoglobulin heavy-chain Smu class switch region. Molecular and Cellular Biology 2007, 27:5921-5932.
146. Yu K., Roy D., Bayramyan M., Haworth I.S., Lieber M.R. Fine-structure analysis of activation-induced deaminase accessibility to class switch region R-loops. Molecular and Cellular Biology 2005, 25:1730-1736.
147. Ronai D., Iglesias-Ussel M.D., Fan M., Li Z., Martin A., Scharff M.D. Detection of chromatin-associated single-stranded DNA in regions targeted for somatic hypermutation. The Journal of Experimental Medicine 2007, 204:181-190.
148. Parsa J.Y., Ramachandran S., Zaheen A., Nepal R.M., Kapelnikov A., Belcheva A., et al. Negative supercoiling creates single-stranded patches of DNA that are substrates for AID-mediated mutagenesis. PLoS Genetics 2012, 8:1-15.
149. Canugovi C., Samaranayake M., Bhagwat A.S. Transcriptional pausing and stalling causes multiple clustered mutations by human activation-induced deaminase. The FASEB Journal 2009, 23:34-44.